Search Within

Linda T Vahdat

Formats
  1. Meeting Abstract (24)
  2. Journal Article (16)
  3. Conference Paper (2)
  4. Review (1)
Groups
  1. Breast Medicine Service (43)
  2. Department of Medicine (43)
  3. Solid Tumor Oncology Division (43)
  4. Survivorship Research (13)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (10)
  6. Hematologic Malignancies, Division of (10)

More Groups

People
  1. John Crown (9)
  2. Larry Norton (9)
  3. David Fennelly (8)
  4. George Raptis (8)
  5. Lilian Reich (8)
  6. Nicola Hamilton (8)

More People

Years
  1. 2022 (2)
  2. 2021 (10)
  3. 2020 (7)
  4. 2019 (5)
  5. 2018 (4)
  6. 2007 (1)

More Years

Publications
  1. Cancer Research (9)
  2. Blood (8)
  3. Annals of Oncology (4)
  4. Journal of Clinical Oncology (4)
  5. Breast Cancer Research and Treatment (3)
  6. Advanced Functional Materials (1)

More Publications

Publishers
  1. American Association for Cancer Research (10)
  2. American Society of Hematology (8)
  3. American Society of Clinical Oncology (4)
  4. Elsevier Inc. (4)
  5. Oxford University Press (4)
  6. Nature Publishing Group (3)

More Publishers

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Tolaney, S. M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Masuda, N.; Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; O'Shaughnessy, J.; Xie, D.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
    Meeting Abstract

    Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Vahdat, L. T.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)
    Meeting Abstract

    Kaufmann, P.; Cortes, J.; Martin, M.; Mayer, I.; Vahdat, L.; Pernas, S.; Schmid, P.; McArthur, H.; Dent, R.; Rugo, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Randomized, doubleblind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; Dong, C.; Walker, L.; Rustia, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Copper depletion as a therapeutic strategy in cancer
    Journal Article

    Lopez, J.; Ramchandani, D.; Vahdat, L.
    Metal Ions in Life Sciences (2019)

    Fulltext@MSK | Save